Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06683534 · ClinicalTrials.gov registry record · Phase 2

Palmitic Acid and Human Microvascular Function

A Phase 2 study, sponsored by Medical College of Wisconsin.

Not yet
Registry status
Phase 2
Development phase
40
Enrollment target

NCT06683534: Clinical Trial Phase 2 study, sponsored by Medical College of Wisconsin.

NCT06683534 is a Phase 2 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06683534, a Phase 2 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

The goal of this study is to learn how a supplement Quercetin can affect microvascular function. Participants will: * give two blood draws of 5 mL each * have a camera placed under the tongue to take pictures of blood vessels * have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.

Primary Outcome

Peripheral microvascular dilation in response to acetylcholine, L-NAME, and sodium nitroprusside infusions will be measured using laser Doppler flowmetry with microdialysis.

Interventions

  • DRUG Placebo
  • DIETARY_SUPPLEMENT Quercetin (dietary supplement)

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-07
Est. Completion 2030-12
Phase Phase 2
Medical College of Wisconsin

447 total trials

What is known before NCT06683534 opens enrollment

NCT06683534 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT06683534 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06683534 about?

NCT06683534 is a clinical study titled "Palmitic Acid and Human Microvascular Function". The goal of this study is to learn how a supplement Quercetin can affect microvascular function. Participants will: * give two blood draws of 5 mL each * have a camera placed under the tongue to take pictures of blood vessels * have 2 laser Doppler microdialysis catheters placed on the forearm to ...

What is the current status of trial NCT06683534?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-07. Estimated completion is 2030-12.

What interventions are being tested in trial NCT06683534?

The interventions under investigation include: Placebo (DRUG), Quercetin (dietary supplement) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06683534?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06683534's enrollment target sits among peer trials

40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT06683534, the US trial registry maintained by the National Library of Medicine. NCT06683534 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.